Malignant Neoplasms of Lip Oral Cavity and Pharynx Withdrawn Phase 1 Trials for Alisertib (DB05220)

IndicationStatusPhase
DBCOND0081505 (Malignant Neoplasms of Lip Oral Cavity and Pharynx)Withdrawn1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02812056Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated MalignanciesTreatment